home

Customized

drug delivery

from technology

to therapy

We empower safe self-administration of liquid drugs through the patient-centric development and manufacture of intelligent injection devices that improve the efficiency and efficacy of therapy.

Reliability and
success in therapy

Our innovative product platforms and related service portfolios assist you every step of the way – leading to an advanced combination of drug and device that is as time-saving and economical for your company as it is safe and convenient in therapy. We support you at every stage – from technology to therapy.

  • 03.06
  • 2022
  • News

Meet us at "Pre-Filled Syringes West Coast" in San Diego, June 13-14

Visit our booth #10 at the "Pre-Filled Syringes West Coast" Show and find out more about our new autoinjector PiccoJect™ and our self-injection devices. Let's talk about your needs and how we can support you!

  • 01.06
  • 2022
  • News

Haselmeier is Gold Partner of this year's InnoPack Pharma Confex in Mumbai, India

Meet our experts Saibal Sengupta, Chris Muenzer and John Tinner from 9-10 June 2022 in the Sahara Star, Mumbai. You will find us at booth B1. We are looking forward to your visit!

  • 18.05
  • 2022
  • News

Haselmeier launches its first fully featured autoinjector at Pharmapack in Paris

medmix Drug Delivery introduces PiccoJect™, a disposable two-step autoinjector designed for subcutaneous injection. The device is being developed in two variants (PiccoJect™ 100 and PiccoJect™ 225) for a standard 1 ml long or 2.25 ml pre-filled glass or plastic syringes.

  • Our services for your projects

  • Our services for your projects

  • Our services for your projects

  • Our services for your projects

Clinical trials

Haselmeier is ideally placed to support you during your clinical trials – and beyond. Our self-injection pens can help reduce risk and shorten time-to-market, helping pharmaceutical companies to address their major priorities in this area.

Learn more

Pharmaceutical manufacturing

Haselmeier offers comprehensive, certified pharmaceutical manufacturing services – from assembly to labeling and packaging. As a result, we are able to support pharmaceutical and biotechnological companies with their drug manufacturing challenges.

Learn more

Product development

Whether you are looking for a customized pen or a platform pen solution, Haselmeier offers product development pathways designed to fit your specific requirements.

Learn more

Medical device regulations

Haselmeier has extensive experience in working with regulatory authorities and can provide comprehensive, efficient support with device registration.

  • Areas of care

  • Areas of care

  • Areas of care

  • Areas of care

Diabetes GLP-1

Haselmeier offers pen solutions that support safe and efficient self-injection of GLP-1 – helping diabetes patients to manage their condition, and so aiding efforts to reduce costs and improve quality of care.

Diabetes Insulin

Haselmeier offers customizable injection pens and platform solutions that help type 1 and type 2 diabetes patients to self-administer insulin, promoting better compliance and more effective treatment.

Osteoporosis

We support convenience and compliance in osteoporosis treatment. The D-Flex™ pen can significantly improve therapy efficiency, allowing patients to treat themselves safely and discreetly on a long-term basis.

Oncology

Haselmeier's customizable pen solutions are suitable for use in some areas of oncology, supporting quality of care in this growing clinical domain. The solutions could improve patients' quality of life and create a basis for reliable and successful therapy at home.

Connected

Let´s create the future of connected solutions

Our new platform supports a fast way to connected commercial devices and better therapy efficiency for patients around the world.

About

Customized drug

delivery – from

technology to therapy

Ready to tackle your

future challenges

At Haselmeier, we are here to support you from early development and manufacturing to packaging and delivery.